Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 1.4% – Here’s What Happened

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) shares fell 1.4% on Monday . The stock traded as low as $1.10 and last traded at $1.20. 19,166 shares were traded during mid-day trading, a decline of 98% from the average session volume of 1,002,475 shares. The stock had previously closed at $1.22.

Theriva Biologics Stock Down 1.4 %

The stock has a market capitalization of $3.34 million, a P/E ratio of -0.04 and a beta of 1.22. The firm has a 50-day moving average of $1.42.

Hedge Funds Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP bought a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned about 6.13% of Theriva Biologics at the end of the most recent reporting period. Institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.